Published online Mar 27, 2016. doi: 10.4240/wjgs.v8.i3.274
Peer-review started: August 11, 2015
First decision: October 16, 2015
Revised: December 17, 2015
Accepted: December 29, 2015
Article in press: January 4, 2016
Published online: March 27, 2016
AIM: To perform a systematic review and meta-analysis on post-operative complications after surgery for Crohn’s disease (CD) comparing biological with no therapy.
METHODS: PubMed, Medline and Embase databases were searched to identify studies comparing post-operative outcomes in CD patients receiving biological therapy and those who did not. A meta-analysis with a random-effects model was used to calculate pooled odds ratios (OR) and confidence intervals (CI) for each outcome measure of interest.
RESULTS: A total of 14 studies were included for meta-analysis, comprising a total of 5425 patients with CD 1024 (biological treatment, 4401 control group). After biological therapy there was an increased risk of total infectious complications (OR = 1.52; 95%CI: 1.14-2.03, 8 studies) and wound infection (OR = 1.73; 95%CI: 1.12-2.67; P = 0.01, 7 studies). There was no increased risk for other complications including anastomotic leak (OR = 1.19; 95%CI: 0.82-1.71; P = 0.26), abdominal sepsis (OR = 1.22; 95%CI: 0.87-1.72; P = 0.25) and re-operation (OR = 1.12; 95%CI: 0.81-1.54; P = 0.46) in patients receiving biological therapy.
CONCLUSION: Pre-operative use of anti-TNF-α therapy may increase risk of post-operative infectious complications after surgery for CD and in particular wound related infections.
Core tip: Pre-operative use of anti-tumor necrosis factor alpha (TNF-α) therapy increases risks of post-operative infectious complications after surgery for Crohn’s disease, particularly wound sepsis. Surgery should be planned carefully and ideally performed after appropriate cessation of anti-TNF-α therapy to mitigate increased post-operative risks.